Market And Manufacturing Technologies For Protein Drugs Market By Types (Recombinant Human Proteins Drugs, Monoclonal Antibodies, Rituxan, Erbitux, Bacterial Protein, Others), Technology (Rational Protein Design, Irrational Protein Design), Product (Instruments, Reagents, Services And Software), End-Users (Academic Research Institutes, Contract Research Organizations, Pharmaceutical And Biotechnology Companies), Industry Size, Growth, Share And Forecast To 2022
Key Findings
The global market and manufacturing technologies for protein drugs is expected to grow at the CAGR of 16% market during 2015-2022. In 2015 the protein drug market generated more than $705.5 million and is expected to generate revenue more than $1500 million by 2022. The key factors that drives the market are increasing consumption of protein drugs, increasing rate of life style diseases, increasing capital for protein drugs technology, among others. The increasing demand of protein drugs in both, developed and developing countries is also one of the major factor driving the market. The protein drugs technology have obtained significant importance as an increasingly popular advanced treatment. Due to the increase in number of chronic cases such as asthma, multiple sclerosis and diseases like cancer and diabetes has increased the demand of protein drugs. According to world health organization, in 2015 it has been estimated that in U.S. more than 1,658,370 new cancer cases has come in; in which more than 848,200 male cancer cases are there and 810,170 female cancer cases. Due to increase in the number of cases of chronic diseases and deaths the demand in pharmaceuticals has grown rapidly, ultimately increasing the market for protein drugs. The industry itself has experienced huge clinical growth globally, due to its crucial role in creating effective and efficient targeted treatments to prevent a huge number of life-threatening diseases. The advancement of manufacturing technologies such as insect cell culture, cell-free bio-manufacturing, mammalian cell culture and use of genetically modified organisms (GMOs) has also fueled the global protein drug market. The insect cell culture has generated the market revenue of more than $11,310.9 Million in 2015. The major factors which helps to increase the market are increasing cases of chronic desires and increasing demand of culture based vaccines helps to increase the market of insect cell culture which ultimately increase protein drug market. The monoclonal antibodies become the largest market segment of the protein drug market. It has generated more than $38.8 billion revenue in 2014. The use of monoclonal antibodies in therapeutics such as inflammatory diseases, autoimmune and oncology increase the market for overall protein drug technology market.
Market Segment Insights
The global markets and manufacturing technologies for protein drugs is segmented on the basis of types, technology, product and end-users. On the basis of different types, the market is segmented as Recombinant human proteins drugs, Monoclonal antibodies, Rotuman, Erbitux, Bacterial protein drugs, others. The antibodies has proved helpful for the human protein therapeutics because they display a helpful pharmacokinetic profile. After a one injection, they can continue for an extended time in the bloodstream, keeping their biological bustle for many weeks. However, antibodies have also developed to be secreted from mammalian cells, and for various reasons, can’t be indicated in yeast or bacterial cell culture. On the basis of different technology, the market is segmented as rational protein design and irrational protein design. In rational protein design, the scientist utilize full knowledge of the shape and purpose of the protein to make various changes. , On the basis of different product, the market is segmented as instruments, reagents, software and services. On the basis of different end users, the market is segmented as academic-research institutes, contract research organization and pharmaceutical and biological companies.
Regional Insights
The report also contains the major regions including North America, Europe, Asia Pacific, and Rest of the World. North America has the largest market share of global markets and manufacturing technologies for protein drugs followed by Europe. The major reason for high growth rate is because of high technology development and high investment in R&D sector helps to increase the market share. European market also have maximum share in the global markets and manufacturing technologies for protein drugs. Asia is expected to be the fastest growing region during the forecast period as there is high increasing population
Competitive Insights
Some of the major market players are Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., BioRexis, Borean Pharma, Bruker Corporation, Compound Therapeutics, Danaher Corporation, Domantis, Dyax, GenScripts USA, Inc. , Johnson & Johnson, Perkinelmer, Inc , Pieris ProteoLab, Sigma-Aldrich Corporation , Thermo Fisher Scientific . Acquisition, mergers and expansions are the key strategies adopted by the market players to sustain in the market. In September 2015 Agilent Technologies Inc. and Seahorse Bioscience announced they have signed a definitive agreement under which Agilent will acquire Seahorse Bioscience, a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics. Similarly in April 2014 Bio-Rad Laboratories, Inc announced the completion of acquisition of GnuBIO, is a developer of droplet-based DNA.
CHAP 1. METHODOLOGY & SCOPE 12
1.1. RESEARCH METHODOLOGY 12
1.2. RESEARCH SCOPE & ASSUMPTIONS 12
1.3. LIST OF DATA SOURCES 12
CHAP 2. EXECUTIVE SUMMARY 13
2.1. GLOBAL MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS SUMMARY & KEY BUYING CRITERIA 13
2.2. GLOBAL MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS OUTLOOK 13
2.3. MARKET SEGMENTATION ANALYSIS 13
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 13
2.5. GLOBAL MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS VALUE CHAIN ANALYSIS 13
2.6. VENDOR LANDSCAPE 13
CHAP 3. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS DETERMINENTS 14
3.1. MARKET DRIVER ANALYSIS 14
3.2. MARKET RESTRAINT ANALYSIS 14
3.3. KEY OPPORTUNITIES 14
3.4. CHALLENGES 14
CHAP 4. INDUSTRY ANALYSIS 15
4.1. GLOBAL MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS – PORTER’S FIVE FORCE MODEL 15
4.2. GLOBAL MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS – PESTEL ANALYSIS 15
4.3. GLOBAL MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS – GAP ANALYSIS 15
CHAP 5. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY TYPES , 2012-2022 ($ BILLION) 16
5.1. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY RECOMBINANT HUMAN PROTEINS DRUGS 2012-2022($ BILLION) 16
5.2. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY MONOCLONAL ANTIBODIES 2012-2022($ BILLION) 16
5.3. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY RITUXAN 2012-2022($ BILLION) 16
5.4. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY ERBITUX 2012-2022($ BILLION) 16
5.5. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY BACTERIAL PROTEIN 2012-2022($ BILLION) 16
5.6. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY OTHERS 2012-2022($ BILLION) 16
CHAP 6. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY TECHNOLOGY , 2012-2022 ($ BILLION) 17
6.1. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY RATIONAL PROTEIN DESIGN 2012-2022($ BILLION) 17
6.2. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY IRRATIONAL PROTEIN DESIGN 2012-2022($ BILLION) 17
CHAP 7. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY PRODUCT, 2012-2022 ($ BILLION) 18
7.1. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY INSTRUMENTS 2012-2022($ BILLION) 18
7.2. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY REAGENTS 2012-2022($ BILLION) 18
7.3. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY SERVICES AND SOFTWARE 2012-2022($ BILLION) 18
CHAP 8. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY END-USERS, 2012-2022 ($ BILLION) 19
8.1. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY ACADEMIC RESEARCH INSTITUTES 2012-2022($ BILLION) 19
8.2. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY CONTRACT RESEARCH ORGANIZATIONS 2012-2022($ BILLION) 19
8.3. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 2012-2022($ BILLION) 19
CHAP 9. GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS , REGIONAL OUTLOOK 2012-2022 ($ BILLION) 20
9.1. GLOBAL MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS BY REGION 2012-2022 ($ BILLION) 20
9.2. NORTH AMERICA 20
9.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 20
9.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 20
9.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 20
9.2.3.1. U.S. 20
9.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 20
9.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 20
9.2.3.2. CANADA 20
9.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 20
9.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 20
9.3. EUROPE 20
9.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 20
9.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 20
9.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 20
9.3.3.1. GERMANY 20
9.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 21
9.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 21
9.3.3.2. UK 21
9.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 21
9.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 21
9.3.3.3. FRANCE 21
9.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 21
9.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 21
9.3.3.4. SPAIN 21
9.3.3.4.1. SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 21
9.3.3.4.2. SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 21
9.3.3.5. REST OF EUROPE 21
9.3.3.5.1. RUSSIA MARKET ESTIMATES AND FORECAST2012-2022($BILLION) 22
9.3.3.5.2. OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 22
9.4. ASIA PACIFIC 22
9.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 22
9.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 22
9.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 22
9.4.3.1. CHINA 22
9.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 22
9.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 22
9.4.3.2. INDIA 22
9.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 22
9.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 22
9.4.3.3. JAPAN 22
9.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 22
9.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 22
9.4.3.4. OTHERS 22
9.4.3.4.1. OTHER MARKET ESTIMATES AND FORECASTS 2012-2022($BILLION) 23
9.4.3.4.2. OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 23
9.5. MIDDLE EAST & AFRICA 23
9.5.1. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
9.5.2. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
9.6. LATIN AMERICA 23
9.6.1. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
9.6.2. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
9.6.2.1. BRAZIL 23
9.6.2.1.1. BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
9.6.2.1.2. BRAZIL MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
CHAP 10. COMPETITIVE LANDSCAPE 24
10.1. AGILENT TECHNOLOGIES, INC 25
10.1.1. COMPANY OVERVIEW 25
10.1.2. SCOT ANALYSIS 25
10.1.3. PRODUCT BENCHMARKING 25
10.1.4. STRATEGIC INITIATIVES 25
10.2. BIO-RAD LABORATORIES, INC 25
10.2.1. COMPANY OVERVIEW 25
10.2.2. SCOT ANALYSIS 25
10.2.3. PRODUCT BENCHMARKING 25
10.2.4. STRATEGIC INITIATIVES 25
10.3. BIOREXIS 25
10.3.1. COMPANY OVERVIEW 25
10.3.2. SCOT ANALYSIS 25
10.3.3. PRODUCT BENCHMARKING 25
10.3.4. STRATEGIC INITIATIVES 25
10.4. BOREAN PHARMA 25
10.4.1. COMPANY OVERVIEW 25
10.4.2. SCOT ANALYSIS 25
10.4.3. PRODUCT BENCHMARKING 25
10.4.4. STRATEGIC INITIATIVES 25
10.5. BRUKER CORPORATION 25
10.5.1. COMPANY OVERVIEW 25
10.5.2. SCOT ANALYSIS 25
10.5.3. PRODUCT BENCHMARKING 25
10.5.4. STRATEGIC INITIATIVES 25
10.6. COMPOUND THERAPEUTICS 25
10.6.1. COMPANY OVERVIEW 25
10.6.2. SCOT ANALYSIS 26
10.6.3. PRODUCT BENCHMARKING 26
10.6.4. STRATEGIC INITIATIVES 26
10.7. DANAHER CORPORATION 26
10.7.1. COMPANY OVERVIEW 26
10.7.2. SCOT ANALYSIS 26
10.7.3. PRODUCT BENCHMARKING 26
10.7.4. STRATEGIC INITIATIVES 26
10.8. DOMANTIS 26
10.8.1. COMPANY OVERVIEW 26
10.8.2. SCOT ANALYSIS 26
10.8.3. PRODUCT BENCHMARKING 26
10.8.4. STRATEGIC INITIATIVES 26
10.9. DYAX 26
10.9.1. COMPANY OVERVIEW 26
10.9.2. SCOT ANALYSIS 26
10.9.3. PRODUCT BENCHMARKING 26
10.9.4. STRATEGIC INITIATIVES 26
10.10. GENSCRIPTS USA, INC. 26
10.10.1. COMPANY OVERVIEW 26
10.10.2. SCOT ANALYSIS 26
10.10.3. PRODUCT BENCHMARKING 26
10.10.4. STRATEGIC INITIATIVES 26
10.11. JOHNSON & JOHNSON 26
10.11.1. COMPANY OVERVIEW 26
10.11.2. SCOT ANALYSIS 26
10.11.3. PRODUCT BENCHMARKING 26
10.11.4. STRATEGIC INITIATIVES 27
10.12. PERKINELMER, INC 27
10.12.1. COMPANY OVERVIEW 27
10.12.2. SCOT ANALYSIS 27
10.12.3. PRODUCT BENCHMARKING 27
10.12.4. STRATEGIC INITIATIVES 27
10.13. PIERIS PROTEOLAB 27
10.13.1. COMPANY OVERVIEW 27
10.13.2. SCOT ANALYSIS 27
10.13.3. PRODUCT BENCHMARKING 27
10.13.4. STRATEGIC INITIATIVES 27
10.14. SIGMA-ALDRICH CORPORATION 27
10.14.1. COMPANY OVERVIEW 27
10.14.2. SCOT ANALYSIS 27
10.14.3. PRODUCT BENCHMARKING 27
10.14.4. STRATEGIC INITIATIVES 27
10.15. THERMO FISHER SCIENTIFIC 27
10.15.1. COMPANY OVERVIEW 27
10.15.2. SCOT ANALYSIS 27
10.15.3. PRODUCT BENCHMARKING 27
10.15.4. STRATEGIC INITIATIVES 27
TABLE 1 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY TYPES , 2012-2022 ($ BILLION) 28
TABLE 2 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY RECOMBINANT HUMAN PROTEINS DRUGS 2012-2022($ BILLION) 28
TABLE 3 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY MONOCLONAL ANTIBODIES 2012-2022($ BILLION) 28
TABLE 4 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY RITUXAN 2012-2022($ BILLION) 28
TABLE 5 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY ERBITUX 2012-2022($ BILLION) 28
TABLE 6 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY BACTARIAL PROTEIN 2012-2022($ BILLION) 28
TABLE 7 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY OTHERS 2012-2022($ BILLION) 28
TABLE 8 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY TECHNOLOGY , 2012-2022 ($ BILLION) 28
TABLE 9 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY RATIONAL PROTEIN DESIGN 2012-2022($ BILLION) 28
TABLE 10 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY IRRATIONAL PROTEIN DESIGN 2012-2022($ BILLION) 28
TABLE 11 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY PRODUCT, 2012-2022 ($ BILLION) 28
TABLE 12 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY INSTRUMENTS 2012-2022($ BILLION) 28
TABLE 13 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY REAGENTS 2012-2022($ BILLION) 29
TABLE 14 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY SERVICES AND SOFTWARE 2012-2022($ BILLION) 29
TABLE 15 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY END-USERS, 2012-2022 ($ BILLION) 29
TABLE 16 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY ACADEMIC RESEARCH INSTITUTES 2012-2022($ BILLION) 29
TABLE 17 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY CONTRACT RESEARCH ORGANIZATIONS 2012-2022($ BILLION) 29
TABLE 18 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BY PHARMACEUTICAL AND& BIOTECHNOLOGY COMPANIES 2012-2022($ BILLION) 29
TABLE 19 NORTH AMERICA MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 29
TABLE 20 NORTH AMERICA MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST BY REGION, 2012 – 2022 ($ BILLION) 29
TABLE 21 NORTH AMERICA MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 29
TABLE 22 U.S. MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 29
TABLE 23 U.S. MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 29
TABLE 24 CANADA MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 29
TABLE 25 CANADA MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 –2022 ($ BILLION) 29
TABLE 26 CANADA MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 29
TABLE 27 EUROPE MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 29
TABLE 28 EUROPE MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST BY REGION, 2012 – 2022 ($ BILLION) 29
TABLE 29 EUROPE MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 30
TABLE 30 GERMANY MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 30
TABLE 31 MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 30
TABLE 32 UK MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 30
TABLE 33 UK MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 30
TABLE 34 ASIA PACIFIC MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 30
TABLE 35 ASIA PACIFIC MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST BY REGION, 2012 – 2022 ($ BILLION) 30
TABLE 36 ASIA PACIFIC MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 30
TABLE 37 CHINA MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 30
TABLE 38 CHINA MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 30
TABLE 39 INDIA MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 30
TABLE 40 INDIA MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 30
TABLE 41 JAPAN MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 30
TABLE 42 JAPAN MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 30
TABLE 43 MIDDLE EAST & AFRICA MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 30
TABLE 44 MIDDLE EAST & AFRICA MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 30
TABLE 45 CENTRAL & SOUTH AMERICA MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 30
TABLE 46 CENTRAL & SOUTH AMERICA MARKET AND MANUFACTURING TECHNOLOGY FOR PROTEIN DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION 31
FIGURE 1 MARKET SHARE BY REGIONS 31
FIGURE 2 UNITED STATES MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
FIGURE 3 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
FIGURE 4 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
FIGURE 5 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
FIGURE 6 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
FIGURE 7 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
FIGURE 8 APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
FIGURE 9 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
FIGURE 10 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
FIGURE 11 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
FIGURE 12 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
FIGURE 13 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 32
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)